Hyundai Pharm revealed promising phase 2 clinical trial results of its groundbreaking diabetes medication, HD-6277, at the 84th American Diabetes Association (ADA) Scientific Sessions. The event took place at the Orlando Convention Center in Orlando, Florida, from Friday to Monday.
HD-6277 is a pioneering GPR40 agonist that stimulates the GPR40 receptor on pancreatic beta cells, promoting insulin secretion and regulating blood glucose levels. Notably, HD-6277 poses no risk of hypoglycemia and does not lead to metabolic diseases such as sarcopenia, critical factors when selecting a diabetes treatment, according to Hyundai Pharm.
During the ADA sessions, Professor Lee Yong-ho of Severance Hospital presented the phase 2 results of HD-6277. The findings highlighted significant glycemic control and safety, with a reduction in glycated hemoglobin levels by 0.73 percent and 0.85 percent following the administration of 50mg and 100mg doses, respectively. Glycated hemoglobin is a key marker for diabetes management.
Initially, Hyundai Pharm conducted phase 1 trials of HD-6277 in Germany and secured approval from the U.S. Food and Drug Administration (FDA) for phase 2 trials. However, due to the Covid-19 pandemic, the phase 2 trial was conducted in Korea.
“The presentation at the ADA sessions underscores the remarkable efficacy of HD-6277 and its potential as a first-in-class drug,” stated Hyundai Pharm CEO Lee Sang-joon. “Our goal is to advance public health by developing next-generation diabetes treatments that address unmet needs, as only 25 percent of current diabetes medications achieve target blood sugar levels.”
With these encouraging results, Hyundai Pharm continues to push the boundaries in diabetes treatment, aiming to provide innovative solutions for effective blood glucose management.
Related topics:
Investigating the Anti-Diabetic Potential of Camellia sinensis Leaf Extract: An In Vitro Analysis
Calls for Early Gestational Diabetes Testing Gain Momentum Among Researchers
Global Type 1 Diabetes Mortality and Disability Decline, Elderly Care Improves
